NCT04254640 is a Phase 2 clinical trial of Cladribine Injection in Acute Myeloid Leukemia, sponsored by Sun Yat-sen University.

Who is sponsoring NCT04254640?

NCT04254640 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04254640?

Interventions in NCT04254640: Cladribine Injection, Aclarubicin, G-CSF, cytarabine.

What condition does NCT04254640 study?

NCT04254640 studies Acute Myeloid Leukemia, Elderly Patients, Newly Diagnosed.

Is NCT04254640 still recruiting?

NCT04254640 is currently status unknown. Last updated 17 December 2020.

Last reviewed 2020-12-17 · How we verify

NCT04254640

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Status unknown Phase 2 Last updated 17 December 2020

What this trial tests

Phase 2 trial testing Cladribine Injection in Acute Myeloid Leukemia in 34 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
1 June 2023

31 December 2023

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	1 March 2021
Primary completion	1 June 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Cladribine Injection
Aclarubicin (ACLARUBICIN) — full drug profile →
G-CSF (g-csf) — full drug profile →
cytarabine — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Elderly Patients — all drugs for Elderly Patients →
Newly Diagnosed — all drugs for Newly Diagnosed →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 90, any sex, with Acute Myeloid Leukemia or Elderly Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators conducted a phase II trial that evaluated the efficacy and safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and aclarubicin) in elderly patients with AML.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Selagibenzophenone B and Its Derivatives: <b>SelB-1</b>, a Dual Topoisomerase I/II Inhibitor Identified through In Vitro and In Silico Analyses.
Dönmez S, Lapinskaite R, Atalay HN, Tokay E, et al · · 2024 · cited 1× · PMID 39184056 · DOI 10.1021/acsbiomedchemau.4c00027

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04254640 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 17 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04254640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing